| After 2017 (group 2) | Before 2017 (group 1) | Total | p-value |
N = 15 | N = 32 | N = 47 |
| |
AGE | 10.9 ± 4.93 | 9.59 ± 5.06 | 10.0 ± 5.01 | 0.397 |
M n (%) | 11 (73.3%) | 22 (68.8%) | 33 (70.2%) |
|
Referral health facility Tertiary hospital | 7 (46.7%) | 3 | 10 | 0.001 |
Secondary hospital | 5 (33.3%) | 28 | 33 |
|
Private practice F n (%) | 3 (0.2%) 4 (26.7%) | 1 10 (31.2%) | 4 14 (29.8%) |
1.000 |
LAL | 10 (6.67%) | 28 (21.9%) | 8 (17.0%) | 0.065 |
LAM | 5 (6.67%) | 0 (0.00%) | 1 (2.13%) |
|
Time since diagnosis (month) | 2.45 ± 2.87 | 4.88 ± 4.74 | 4.10 ± 4.36 | 0.036 |
Karnosky score: |
|
|
| 0.002 |
40 - 50 | 0 (0.00%) | 11 (34.26%) | 9 (19.1%) |
|
70 | 15 (100%) | 12 (37.5%) | 27 (57.4%) |
|
80 - 100 | 0 (0.00%) | 9 (11.25%) | 2 (4.26%) |
|
WBC (G/L) Moy ± sd | 57.5 ± 51.2 | 76.2 ± 77.5 | 70.3 ± 70.2 | 0.331 |
Hb (G/L) | 7.34 ± 2.22 | 3.31.0 ± 1.41 | 5.11.0 ± 3.21 |
|
Platelet (G/L) | 78.9 ± 22.5 | 71.5 ± 43.5 | 74.7 ± 33.5 |
|
Follow up in month | 5.92 ± 4.79 | 5.65 ± 11.6 | 5.74 ± 9.91 | 0.910 |